Cyclerion Therapeutics Sets Sept 4 Record Date for CVR Distribution

What Happened
Cyclerion Therapeutics, Inc. (CYCN) filed an 8-K on August 25, 2026 announcing that its board fixed the close of business on September 4, 2026 as the record date for the previously announced contingent value rights (CVR) distribution. The CVRs will be distributed to holders of record of Cyclerion common stock and the Company’s Series A Preferred Stock in connection with Cyclerion’s planned merger with Korsana Biosciences, Inc. The filing also includes forward-looking statements and directs investors to the Form S-4 and related proxy/prospectus materials for more detail.

Key Details

• Filing date: August 25, 2026; record date set for close of business on September 4, 2026.
• CVRs to be distributed to holders of Cyclerion common stock and Series A Preferred Stock in connection with the proposed merger with Korsana.
• Filing reiterates forward-looking statements and lists risks (e.g., conditions to closing, financing, regulatory approvals, Nasdaq listing status).
• Cyclerion has filed a Form S-4 (proxy statement/prospectus) with the SEC and urges investors to read it for full details; proxies/voting and CVR terms will be in those materials.

Why It Matters
For investors, the record date determines who is eligible to receive the CVRs if the merger proceeds. The 8-K does not change the terms of the merger or guarantee any CVR payments—those details (including transferability, listing, and payment conditions) are in the Form S-4 and related materials. Retail investors should review the Form S-4/proxy materials and monitor merger progress, shareholder vote requirements, and any updates about financing or regulatory approvals before making voting or investment decisions.